Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 3/20 | 0.47 |
| ▸ | S100A4 | P26447 | 2/20 | 0.47 |
| ▸ | TDP2 | O95551 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 4/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10907985 | 0.87 | TDP2 (0.48) | PTPRCS100A4TDP2CAPN9CASP3 | |
| SCHEMBL1811557 | 0.84 | PTPRC (0.45) | PTPRCS100A4TDP2HTR1ACAPN9 | |
| SCHEMBL20500978 | 0.84 | PTPRC (0.45) | PTPRCS100A4TDP2HTR1ACAPN9 | |
| SCHEMBL2246368 | 0.81 | ACHE (0.58) | PTPRCS100A4TDP2HTR1AALDH1A1 | |
| SCHEMBL1097849 | 0.75 | TDP2 (0.46) | PTPRCS100A4TDP2CAPN9CASP3 | |
| SCHEMBL15617648 | 0.75 | PNMT (0.45) | PTPRCS100A4TDP2HTR1APNMT | |
| SCHEMBL17675410 | 0.74 | METAP1 (0.44) | PTPRCS100A4TDP2TDP1TLR9 | |
| SCHEMBL11563863 | 0.73 | TSHR (0.39) | ALDH1A1CYP3A4MEN1KMT2AMAPT | |
| SCHEMBL9592880 | 0.73 | ACHE (0.60) | HTR1ACASP3ALDH1A1CYP3A4PNMT | |
| Hydrochloric Acid SCHEMBL9591976 | 0.73 | HTR1A (0.44) | PTPRCS100A4TDP2HTR1ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1801108-B9 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-11-20 | — | — | EP | disclosed |
| EP-1801108-B1 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7935700-B2 | Morpholine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20070265257-A1 | Morpholine Compound | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1801108-A1 | MORPHOLINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2007-06-27 | — | — | EP | disclosed |
| EP-1157014-B1 | POLYCYCLIC 2-AMINO-DIHYDROTHIAZOLE SYSTEMS, METHOD FOR THE PRODUCTION THEREOF AND THEIR UTILIZATION AS MEDICAMENT | AVENTIS PHARMA GMBH (DE) | 2005-08-24 | — | — | EP | disclosed |
| EP-1157014-A1 | POLYCYCLIC 2-AMINO-DIHYDROTHIAZOLE SYSTEMS, METHOD FOR THE PRODUCTION THEREOF AND THEIR UTILIZATION AS MEDICAMENT | Aventis Pharma Deutschland GmbH (DE) | 2001-11-28 | — | — | EP | disclosed |
| US-6235763-B1 | THERAPY FOR EATING DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-05-22 | — | — | US | disclosed |
| WO-2000051994-A1 | POLYCYCLIC 2-AMINO-DIHYDROTHIAZOLE SYSTEMS, METHOD FOR THE PRODUCTION THEREOF AND THEIR UTILIZATION AS MEDICAMENT | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-09-08 | — | — | WO | disclosed |
| US-4174397-A | TREATMENT OF OBESITY AND LIPID METABOLISM DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265257-A1 | Morpholine Compound | CCR3, CCR1, CCR4 | PTPRC 3903/4885S100A4 2476/4885TDP2 4119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.